AU2004258821A1 - Antibacterial methods and compositions - Google Patents

Antibacterial methods and compositions Download PDF

Info

Publication number
AU2004258821A1
AU2004258821A1 AU2004258821A AU2004258821A AU2004258821A1 AU 2004258821 A1 AU2004258821 A1 AU 2004258821A1 AU 2004258821 A AU2004258821 A AU 2004258821A AU 2004258821 A AU2004258821 A AU 2004258821A AU 2004258821 A1 AU2004258821 A1 AU 2004258821A1
Authority
AU
Australia
Prior art keywords
aureus
mupirocin
composition
mrsi
trna synthetase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004258821A
Other languages
English (en)
Inventor
Ian A. Critchley
Joseph Guiles
Nebojsa Janjic
Theodore M. Tarasow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiovascular Systems Inc
Original Assignee
Replidyne Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replidyne Inc filed Critical Replidyne Inc
Publication of AU2004258821A1 publication Critical patent/AU2004258821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004258821A 2003-05-01 2004-05-03 Antibacterial methods and compositions Abandoned AU2004258821A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46737703P 2003-05-01 2003-05-01
US60/467,377 2003-05-01
US48648203P 2003-07-10 2003-07-10
US60/486,482 2003-07-10
PCT/US2004/013614 WO2005009336A2 (en) 2003-05-01 2004-05-03 Antibacterial methods and compositions

Publications (1)

Publication Number Publication Date
AU2004258821A1 true AU2004258821A1 (en) 2005-02-03

Family

ID=34107519

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004258821A Abandoned AU2004258821A1 (en) 2003-05-01 2004-05-03 Antibacterial methods and compositions

Country Status (6)

Country Link
US (1) US20040224981A1 (enExample)
EP (1) EP1619947A4 (enExample)
JP (1) JP2007502861A (enExample)
AU (1) AU2004258821A1 (enExample)
CA (1) CA2523651A1 (enExample)
WO (1) WO2005009336A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004218481A1 (en) * 2003-03-03 2004-09-16 Replidyne Inc Substituted thiophenes with antibacterial activity
AU2006226750B2 (en) 2005-03-23 2012-07-19 Oculus Innovative Sciences, Inc. Method of treating skin ulcers using oxidative reductive potential water solution
CA2606804A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Antimicrobial agents
WO2007085018A2 (en) 2006-01-20 2007-07-26 Oculus Innovative Sciences, Inc. Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
AU2007300290B2 (en) * 2006-09-26 2012-11-15 Crestone, Inc. Enantiomeric compounds with antibacterial activity
ES2392897T3 (es) * 2006-09-26 2012-12-14 Crestone, Inc. Compuestos tienopiridona sustituidos con actividad antibacteriana
WO2010099477A2 (en) 2009-02-27 2010-09-02 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
CN102480972B (zh) 2009-06-15 2014-12-10 奥古露丝创新科学公司 含有次氯酸的溶液及其使用方法
JP6066900B2 (ja) 2010-04-26 2017-01-25 エータイアー ファーマ， インコーポレイテッド システイニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
ES2638311T3 (es) 2010-04-27 2017-10-19 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, diagnósticas y de anticuerpos relacionadas con fragmentos de proteína de treonil ARNt sintetasas
JP6008837B2 (ja) 2010-04-28 2016-10-19 エータイアー ファーマ， インコーポレイテッド アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
WO2011139907A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CA2797799C (en) 2010-05-03 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
JP6008843B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド グルタミル−プロリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
AU2011256366C1 (en) 2010-05-17 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
CA2804416C (en) 2010-07-12 2020-04-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CA2804278C (en) 2010-07-12 2021-07-13 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
KR20130102534A (ko) 2010-07-12 2013-09-17 에이티와이알 파마, 인코포레이티드 히스티딜­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
JP5964304B2 (ja) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2624857B1 (en) 2010-10-06 2017-08-02 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl trna synthetases
JP2013538868A (ja) * 2010-10-08 2013-10-17 ヘルパービー セラピューティクス リミテッド 新規な組成物
WO2012054738A1 (en) * 2010-10-22 2012-04-26 Brown University Combination of an aminoacyl - trna synthetase inhibitor with a further antibacterial agent for attenuating multiple drug resistance
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
CA2858613A1 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
CA2869717C (en) 2012-04-13 2022-09-06 Becton, Dickinson And Company Reflex testing of samples using residual materials from a prior test
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
JP2019196307A (ja) 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環アミド化合物
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
US11261201B2 (en) 2018-01-12 2022-03-01 President And Fellows Of Harvard College TRNA synthetase inhibitors
TW202214611A (zh) * 2020-08-25 2022-04-16 大陸商杭州中美華東製藥有限公司 莫匹羅星的提取方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1196284A (en) * 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
GB8415579D0 (en) * 1984-06-19 1984-07-25 Beecham Group Plc Compounds
IE59628B1 (en) * 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
AU692486B2 (en) * 1993-10-22 1998-06-11 Smithkline Beecham Corporation Pharmaceutical or veterinary composition comprising mupirocin or a salt thereof in a cream base
GB9424562D0 (en) * 1994-12-06 1995-01-25 Giltech Ltd Product
GB9507825D0 (en) * 1995-04-18 1995-05-31 Wet Pieter M De Method of treatment
US5726195A (en) * 1995-07-28 1998-03-10 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
US6169102B1 (en) * 1996-06-25 2001-01-02 Takeda Chemical Industries, Ltd. Oxazolone derivatives and their use as anti-Helicobacter pylori agent
US6448059B1 (en) * 1996-09-13 2002-09-10 Thomas Jefferson University Methods and composition for inhibition of tRNA activities
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US5939458A (en) * 1997-09-22 1999-08-17 Henry; James P. Reduction of hair growth
JP2002513005A (ja) * 1998-04-29 2002-05-08 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｍｒｓ阻害剤および殺菌剤用のキノロン類
AU5822099A (en) * 1998-09-18 2000-04-10 Cubist Pharmaceuticals, Inc. Tetracyclic heterocycles as antimicrobial agents
GB9822241D0 (en) * 1998-10-12 1998-12-09 Smithkline Beecham Plc Novel compounds
AU769652B2 (en) * 1999-05-05 2004-01-29 Cubist Pharmaceuticals, Inc. Novel prolines as antimicrobial agents
AU776773B2 (en) * 1999-05-05 2004-09-23 Cubist Pharmaceuticals, Inc. Novel catechols as antimicrobial agents
JP2003500397A (ja) * 1999-05-19 2003-01-07 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｍｒｓ阻害剤としての２−ｎｈ−ピリドンおよびピリミドン
GB9911594D0 (en) * 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
IL137363A (en) * 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
GB0228545D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compounds
GB0302546D0 (en) * 2003-02-04 2003-03-12 Glaxo Group Ltd Novel compounds
AU2004218481A1 (en) * 2003-03-03 2004-09-16 Replidyne Inc Substituted thiophenes with antibacterial activity
DE10318991A1 (de) * 2003-04-25 2004-11-18 Heraeus Kulzer Gmbh & Co. Kg Poröser Körper mit antibiotischer Beschichtung, Verfahren zur Herstellung sowie Verwendung

Also Published As

Publication number Publication date
EP1619947A2 (en) 2006-02-01
WO2005009336A2 (en) 2005-02-03
EP1619947A4 (en) 2006-05-31
WO2005009336A9 (en) 2005-04-14
WO2005009336A3 (en) 2005-10-13
JP2007502861A (ja) 2007-02-15
CA2523651A1 (en) 2005-02-03
US20040224981A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
AU2004258821A1 (en) Antibacterial methods and compositions
RU2569307C1 (ru) Азотсодержащие соединения и их применение
RU2609259C2 (ru) Пиримидиновые ингибиторы гиразы и топоизомеразы iv
US12150937B2 (en) NLRP3 modulators
KR20080038380A (ko) 항균제로서의 퀴놀린 유도체
RU2527769C2 (ru) Производные 5-гидроксиметилоксазолидин-2-она для лечения бактериальных кишечных заболеваний
US12187706B2 (en) NLRP3 modulators
KR20150089086A (ko) 박테리아 감염을 치료하기 위한 조성물 및 방법
JP6411482B2 (ja) 窒素含有化合物およびその使用
US20170056405A1 (en) Methods and compositions for treating bacterial infection
US12016874B2 (en) Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections
EP1618106B1 (en) Carbacephem beta-lactam antibiotics
KR20170032480A (ko) 항균제 및 타조박탐을 포함하는 조성물
KR101329587B1 (ko) 항균제로서의 퀴놀린 유도체
US20180042928A1 (en) Methods and compositions for treating bacterial infection
AU2019349438B2 (en) Indane derivatives for use in the treatment of bacterial infection
AU2003303953B2 (en) Antibacterial pyrazole carboxylic acid hydrazides
US20210094954A1 (en) Preparation methods and applications of 3,5-disubstituted methylpyrazolo[1,5-a]pyrimidine-7-hydroxylic salts
CN110981888B (zh) N-芳基二硫吡咯酮脲类和氨基酯类衍生物及其制备和应用
KR20080021156A (ko) 항균제로서 퀴놀린 유도체
EP2285802B1 (en) Oxo-imidazolyl compounds having antibacterial activity
CN120665042A (zh) 活性氧激活型抗菌前药及其在治疗细菌感染中的应用
US20250161266A1 (en) Antibacterial 4.5 Diaryl-Thiophen-2-YL Hexafluoropropan-2-OLS
CN120424016A (zh) 一种多卤代喹唑啉酮生物碱及其在抗金黄色葡萄球菌中的应用
KR101318181B1 (ko) 항균제로서의 퀴놀린 유도체

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application